Carly Whyte

Dr Carly Whyte

Research Fellow

Centre for Cancer Biology

College of Health

Carly Whyte is an early-career researcher with expertise in the cellular and molecular mechanisms underlying immune-mediated pathology. Her research focuses on understanding how our immune systems can recognise and respond to cancer, with a view towards developing new immunotherapies for patients with solid tumours. She is supported by a Passe and Williams Junior Fellowship.
Dr Whyte holds a PhD in Immunology from the University of Adelaide, during which she discovered a previously unknown regulator of immune cell migration into tumours called ACKR4. She was then appointed as a postdoctoral research scientist at the Babraham Institute, Cambridge, UK and a Research Associate at Fitzwilliam College, University of Cambridge. During this postdoctoral training with Prof. Adrian Liston, Dr Whyte elucidated signaling networks of the cytokine IL-2, discovering novel mechanisms of action for this protein and identifying new regulatory networks which explained some of the common side-effects of therapeutic use of IL-2.

Year Citation
2023 Roca, C. P., Burton, O., Neumann, J., Tareen, S., Whyte, C. E., Gergelits, V., . . . Liston, A. (2023). A cross entropy test allows quantitative statistical comparison of t-SNE and UMAP representations. Cell Reports Methods, 3(1, article no. 100390), 1-15.
DOI
2022 Yshii, L., Pasciuto, E., Bielefeld, P., Mascali, L., Whyte, C. E., & Liston, A. (2022). Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation. Nature Immunology, 23(6), 878-891.
DOI
2022 Whyte, C. E., Tumes, D. J., Liston, A., & Burton, O. T. (2022). Do more with less: improving high parameter cytometry through overnight staining. Current Protocols, 2(11, article no. e589), 1-20.
DOI Scopus35 WoS32 Europe PMC34
2022 Whyte, C. E., Singh, K., Burton, O. T., Aloulou, M., & Liston, A. (2022). Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits. Journal of Experimental Medicine, 219(7, article no. e20212391), 1-30.
DOI
2021 Roca, C. P., Burton, O. T., Gergelits, V., Prezzemolo, T., Whyte, C. E., Halpert, R., . . . Liston, A. (2021). AutoSpill is a principled framework that simplifies the analysis of multichromatic flow cytometry data. Nature Communications, 12(1, article no. 2890), 1-16.
DOI
2021 Hill, D. L., Whyte, C. E., Innocentin, S., Le Lee, J., Dooley, J., Wang, J., . . . Linterman, M. A. (2021). Impaired HA-specific T follicular helper cell and antibody responses to influenza vaccination are linked to inflammation in humans. eLife, 10(e70554), 1-30.
DOI Europe PMC37
2020 Nasrallah, R., Imianowski, C. J., Bossini Castillo, L., Grant, F. M., Whyte, C. E., & Roychoudhuri, R. (2020). A distal enhancer at risk locus 11q13.5 promotes suppression of colitis by T.reg cells. Nature, 583(7816), 447-452.
DOI
2020 Pasciuto, E., Burton, O. T., Roca, C. P., Lagou, V., Whyte, C. E., & Liston, A. (2020). Microglia require CD4 T cells to complete the fetal-to-adult transition. Cell, 182(3), 625-640.
DOI
2020 Whyte, C. E., Osman, M., Kara, E. E., Abbott, C., Foeng, J., McKenzie, D. R., . . . McColl, S. R. (2020). ACKR4 restrains antitumor immunity by regulating CCL21. Journal of Experimental Medicine, 217(6), 1-S4.
DOI Scopus29 WoS29 Europe PMC29
2019 Koay, H. -F., Su, S., Amann-Zalcenstein, D., Daley, S. R., Comerford, I., Miosge, L., . . . Godfrey, D. I. (2019). A divergent transcriptional landscape underpins the development and functional branching of MAIT cells. ScienceImmunology, 4(41), eaay6039-1-eaay6039-16.
DOI Scopus84 WoS85 Europe PMC96
2018 Kara, E. E., Bastow, C. R., McKenzie, D. R., Whyte, C. E., Fenix, K. A., Babb, R., . . . McColl, S. R. (2018). Atypical chemokine receptor 4 shapes activated B cell fate. Journal of Experimental Medicine, 215(3), 801-813.
DOI Scopus21 WoS21 Europe PMC23
2017 Boyle, S., Gieniec, K., Gregor, C., Faulkner, J., McColl, S., & Kochetkova, M. (2017). Interplay between CCR7 and Notch1 axes promotes stemness in MMTV-PyMT mammary cancer cells. Molecular Cancer, 16(1), 19-1-19-8.
DOI Scopus26 WoS27 Europe PMC22
2017 McKenzie, D., Kara, E., Bastow, C., Tyllis, T., Fenix, K., Gregor, C., . . . McColl, S. (2017). IL-17-producing γδ T cells switch migratory patterns between resting and activated states. Nature Communications, 8(15632), 15632-1-15632-13.
DOI Scopus101 WoS98 Europe PMC102
2015 Kara, E., McKenzie, D., Bastow, C., Gregor, C., Fenix, K., Ogunniyi, A., . . . McColl, S. (2015). CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells. Nature Communications, 6(8644), 8644-1-8644-1 7.
DOI Scopus114 WoS108 Europe PMC101
2014 Harata-Lee, Y., Turvey, M., Brazzatti, J., Gregor, C., Brown, M., Smyth, M., . . . McColl, S. (2014). The atypical chemokine receptor CCX-CKR regulates metastasis of mammary carcinoma via an effect on EMT. Immunology and Cell Biology, 92(10), 815-824.
DOI Scopus17 WoS18 Europe PMC18
2014 Kara, E., Comerford, I., Fenix, K., Bastow, C., Gregor, C., McKenzie, D., & McColl, S. (2014). Tailored immune responses: novel effector helper T cell subsets in protective immunity. PLoS Pathogens, 10(2), 1003905-1-1003905-15.
DOI Scopus73 WoS65 Europe PMC57
2013 Comerford, I., Harata-Lee, Y., Bunting, M., Gregor, C., Kara, E., & McColl, S. (2013). A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. Cytokine & Growth Factor Reviews, 24(3), 269-283.
DOI Scopus235 WoS230 Europe PMC219
2010 Comerford, I., Bunting, M., Fenix, K., Haylock-Jacobs, S., Litchfield, W., Harata-Lee, Y., . . . McColl, S. (2010). An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation? CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays, 32(12), 1067-1076.
DOI Scopus102 WoS100 Europe PMC90

  • Overcoming immune exhaustion in recurrent head and neck cancer, Garnett Passe & Rodney Williams Memorial Foundation-Conjoint Grant, 01/01/2025 - 31/12/2027

  • Defining the therapeutic potential of eosinophils in melanoma, Australian Melanoma Research Foundation, 01/02/2025 - 31/07/2026

Connect With Me

External Profiles

Other Links